List view / Grid view
Filter the results
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
The FDA has announced its approval of Descovy, a PrEP method therapy, to reduce the risk of HIV-1 infection from sex.
The FDA has given a complete response letter to AstraZeneca for its PT010 treatment, regarding its New Drug Application.
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
A new initiative has already collaboratively reviewed applications for two oncology drugs, allowing for simultaneous decisions in three countries.